Adelaide, Australia, 7th August 2023
GPN Vaccines is pleased to announce that the Phase I clinical trial of Gamma-PN is now fully recruited. The Phase I clinical trial is assessing the safety, tolerability and immunogenicity of Gamma-PN – a novel broad-spectrum pneumococcal vaccine. One hundred and seventeen healthy volunteers aged 50-69 have now been recruited, with the final cohort of 39 participants having received at least one dose of the Gamma-PN vaccine or a placebo or a licensed pneumococcal vaccine currently used in Australia.
GPN Vaccines’ Chief Executive Officer Professor Tim Hirst said “This is an important achievement for any clinical trial and I’d like to thank all of the participants who volunteered to be involved in trialling our novel pneumococcal vaccine. Over the next 8 weeks we’ll collect the final blood samples from the last cohort of participants, and then embark on a comprehensive immunological assessment of the responses to vaccination by Gamma-PN compared to administering a placebo or a licensed pneumococcal vaccine”.
The clinical trial is being conducted at CMAX in Adelaide, one of Australia’s largest and most experienced clinical trial centres, with oversight from Southern Star Research.
The Chief Executive Officer of CMAX Jane Kelly said “This achievement stands testament to our commitment to advancing the future of global healthcare. The entire CMAX team is thrilled to see the results of all our hard work come to fruition. We are immensely grateful to our participants for their contribution, as well as the GPN team for trusting us to help reach such a significant milestone.”
This clinical trial was generously supported by a $1 million grant from the South Australian Government’s Research and Innovation Fund (RIF). Achieving the key milestone of fully recruiting the clinical trial triggers the next tranche of funding.
About GPN Vaccines
GPN Vaccines is a public (unlisted) biotechnology company developing a vaccine against Streptococcus pneumoniae, which is responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections). Each year it causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now 100 different serotypes of S. pneumoniae and the best vaccine currently on the market only protects against 20 of them. GPN Vaccines’ product, called Gamma-PN, is being developed to protect children and adults against all S. pneumoniae strains, regardless of serotype.
Media contacts
Prof Tim Hirst, CEO; tim@gpnvaccines.com, +61 420 942 824
Jane Kelly, CEO; jane.kelly@CMAX.com, +61 8 7088 7900
